Biotherapies developed and manufactured in France in compliance with good practices
Clinical studies based on real animal treatments
Easy to use products, delivered solely by veterinarians
Précédent
Suivant

Vetbiobank obtains Good Manufacturing Practices (GMP) certification.

Vetbiobank, a specialist in animal biotherapies, becomes the first veterinary pharmaceutical company in France to receive GMP certification for its pharmaceutical manufacturing activities.

Vetbiobank has thus reached a new milestone towards obtaining the first MA for its veterinary drug based on canine neonatal stem cells against osteoarthritis in dogs.

Vetbiobank becomes one of the first laboratory to obtain this certification for a patented 3D bioproduction process, in a bioreactor, capable of efficiently meeting the needs of these mass markets.

For Veterinarians only

For Veterinarians only

Ask your veterinarian for the price of a stem cell injection at his clinic.

Product Pipeline

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

CANIPREN

VBX-01
Canine osteoarthritis

CA0102
Atopic dermatitis

CA0103
Atopic dermatitis
Chronic
Inflammatory
Bowel
Disease

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

FELIPREN

FE0101
Gingivostomatitis

FE0102
Chronic kidney
failure

FE0103
Feline arthrosis

Range Product Development & optimization Proof of Concept Pilot study Industrialisation /
Manufacturing
Pivotal study Approval Marketing Launch

EQUIPREN
OMBISTEM

EQ0101
Equine arthrosis